Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions

BMC Infect Dis. 2022 May 2;22(1):420. doi: 10.1186/s12879-022-07410-6.

Abstract

Background: Antimicrobial stewardship programs (ASPs) have become a fundamental pillar in optimizing antimicrobial usage, improving patient care, and reducing antimicrobial resistance (AMR). Herein we evaluated the impact of an ASP on antimicrobial consumption and AMR in Colombia.

Methods: We designed a retrospective observational study and measured trends in antibiotic consumption and AMR before and after the implementation of an ASP using interrupted time series analysis over a 4-year period (24 months before and 24 months after ASP implementation).

Results: ASPs were implemented according to the available resources in each of the institutions. Before ASP implementation, there was a trend toward an increase in the antibiotic consumption of all measured antimicrobials selected. Afterward, an overall decrease in antibiotic consumption was observed. The use of ertapenem and meropenem decreased in hospital wards, while a decrease in the use of ceftriaxone, cefepime, piperacillin/tazobactam, meropenem, and vancomycin was observed in intensive care units. After ASP implementation, the trend toward an increase of oxacillin-resistant Staphylococcus aureus, ceftriaxone-resistant Escherichia coli, and meropenem-resistant Pseudomonas aeruginosa was reversed.

Conclusions: In our study, we showed that ASPs are a key strategy in tackling the emerging threat of AMR and have a positive impact on antibiotic consumption and resistance.

Keywords: Antibiotic resistance; Antimicrobial resistance; Antimicrobial stewardship; Antimicrobial stewardship program; Colombia; Hospital epidemiology.

Publication types

  • Observational Study

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents*
  • Antimicrobial Stewardship*
  • Ceftriaxone
  • Colombia
  • Delivery of Health Care
  • Drug Resistance, Bacterial
  • Humans
  • Meropenem / therapeutic use
  • Methicillin-Resistant Staphylococcus aureus*

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Ceftriaxone
  • Meropenem